BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31396884)

  • 21. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
    Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
    Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of p53 protein in gallbladder carcinoma in North India.
    Misra S; Chaturvedi A; Goel MM; Mehrotra R; Sharma ID; Srivastava AN; Misra NC
    Eur J Surg Oncol; 2000 Mar; 26(2):164-7. PubMed ID: 10744937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer.
    Ghosh M; Sakhuja P; Singh S; Agarwal AK
    Saudi J Gastroenterol; 2013; 19(1):34-9. PubMed ID: 23319036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
    Saetta AA; Papanastasiou P; Michalopoulos NV; Gigelou F; Korkolopoulou P; Bei T; Patsouris E
    Virchows Arch; 2004 Aug; 445(2):179-82. PubMed ID: 15221372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xanthogranulomatous cholecystitis: a clinicopathological study of its association with gallbladder carcinoma.
    Zhuang PY; Zhu MJ; Wang JD; Zhou XP; Quan ZW; Shen J
    J Dig Dis; 2013 Jan; 14(1):45-50. PubMed ID: 23134201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns.
    Hanada K; Itoh M; Fujii K; Tsuchida A; Hirata M; Iwao T; Eguchi N; Sasaki T; Matsubara K; Kajiyama G
    Eur J Cancer; 1997 Jun; 33(7):1136-40. PubMed ID: 9376195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction.
    Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F
    J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
    Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
    Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma.
    Wang SN; Chung SC; Tsai KB; Chai CY; Chang WT; Kuo KK; Chen JS; Lee KT
    Kaohsiung J Med Sci; 2006 Feb; 22(2):53-9. PubMed ID: 16568721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma.
    Moreno M; Pimentel F; Gazdar AF; Wistuba II; Miquel JF
    Ann Hepatol; 2005; 4(3):192-9. PubMed ID: 16177659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas.
    Itoi T; Watanabe H; Yoshida M; Ajioka Y; Nishikura K; Saito T
    Pathol Int; 1997 Aug; 47(8):525-30. PubMed ID: 9293532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma: a retrospective study.
    Kawakami S; Takano S; Fukasawa M; Shindo H; Takahashi E; Fukasawa Y; Hayakawa H; Kuratomi N; Kadokura M; Hosomura N; Amemiya H; Kawaida H; Kono H; Maekawa S; Ichikawa D; Enomoto N
    BMC Cancer; 2021 Nov; 21(1):1245. PubMed ID: 34798839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer.
    Hirosawa T; Ishida M; Ishii K; Kanehara K; Kudo K; Ohnuma S; Kamei T; Motoi F; Naitoh T; Selaru FM; Unno M
    PLoS One; 2018; 13(11):e0206643. PubMed ID: 30395583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.